BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Source: moomoo
Investment Announcement: Brainway has completed an additional investment of $6 million in NeuroLife Ltd., based in Milestone, indicating strong confidence in the company's potential.
Regulatory Approval: This investment follows the FDA's approval of the Proliv™ RX system for MDD, which is expected to enhance the company's market position and product offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.880
Low
19.00
Averages
26.33
High
30.00
Current: 15.880
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay Enters Strategic Equity Financing Agreement with Hopemark
- Strategic Investment: BrainsWay has entered into a strategic equity financing agreement with Hopemark, initially investing $1.5 million with the potential for an additional $1.5 million based on milestones, aimed at enhancing access to and awareness of mental health treatments.
- Partnership Outlook: CEO Hadar Levy stated that this investment will allow BrainsWay to focus on advancing its business and technology while partnering with growth-oriented clinical platforms to enhance its market position.
- Hopemark's Strengths: Hopemark CEO Abid Nazeer emphasized that BrainsWay's investment not only provides growth capital but also brings a deep understanding of interventional psychiatry, aiding Hopemark in scaling efficiently and improving patient outcomes.
- Industry Impact: This collaboration signifies BrainsWay's further commitment to the mental health sector, expected to accelerate the application and market penetration of Deep TMS technology, driving overall business growth.
See More
BrainsWay Ltd Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 35% increase in revenue to $15.5 million for Q1 2026, indicating strong demand and sustained growth potential in the deep TMS market.
- Continued Profitability Improvement: The company achieved its 11th consecutive quarter of profitability with net income exceeding $2.3 million, more than doubling year-over-year, reflecting the effectiveness of its business model and increased market acceptance.
- Accelerated Market Expansion: The company shipped 117 deep TMS systems in the quarter, a 44% increase year-over-year, expanding its total install base to approximately 1,820 systems, thereby solidifying its market position in mental health.
- Increased R&D and Marketing Investment: Despite rising sales and marketing expenses to $4.9 million and R&D expenses to $2.8 million, these investments are expected to drive future product innovation and market expansion, supporting the company's long-term growth strategy.
See More
BrainsWay Q1 Earnings Beat Expectations with Strong Guidance
- Strong Earnings Report: BrainsWay reported Q1 GAAP EPS of $0.06, beating expectations by $0.01, indicating sustained profitability and enhancing its competitive position in the market.
- Significant Revenue Growth: The company achieved Q1 revenue of $15.53 million, a 34.6% year-over-year increase, exceeding market expectations by $0.91 million, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a growth of 27% to 30% compared to 2025, showcasing confidence in future growth prospects.
- Profitability Outlook: The company anticipates operating income to be 13% to 14% of revenue, with adjusted EBITDA expected to range from $12 million to $14 million, indicating an anticipated growth of 86% to 100% over 2025, further solidifying its financial health.
See More
BrainsWay Reports Strong Q1 2026 Financial Results with 35% Revenue Growth
- Significant Revenue Growth: BrainsWay's Q1 2026 revenue surged 35% year-over-year to $15.5 million, indicating strong market demand for its non-invasive neurostimulation treatments and further solidifying its leadership position in the industry.
- Net Income Doubles: The company reported a net income of $2.3 million for Q1, more than doubling from $1.1 million in the prior year, reflecting significant improvements in cost control and operational efficiency, which enhances investor confidence.
- Guidance Reaffirmed: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a 27% to 30% increase year-over-year, while also projecting Adjusted EBITDA of $12 million to $14 million, showcasing confidence in future growth.
- Strong Market Demand: The shipment of 117 Deep TMS systems in Q1, a 44% increase from the previous year, indicates strengthened relationships with enterprise clients and sustained market demand for its products, suggesting ongoing growth potential ahead.
See More
BrainsWay Q1 Earnings Announcement Scheduled
- Earnings Release Date: BrainsWay is set to announce its Q1 earnings on May 13 before market open, with a consensus EPS estimate of $0.05, reflecting a substantial year-over-year increase of 150%, indicating a significant improvement in profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $14.62 million, representing a 26.7% year-over-year growth, which underscores the company's ongoing expansion and increasing customer demand, further solidifying its market position.
- Outstanding Historical Performance: Over the past year, BrainsWay has exceeded EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating stability and reliability in its financial performance.
- Positive Revision Trends: In the last three months, both EPS and revenue estimates have seen three upward revisions with no downward adjustments, reflecting analysts' confidence in the company's future performance, which could positively impact its stock price.
See More
BrainsWay Advances TMS Treatment Coverage Policy Changes
- Policy Update: In late 2025, Optum/United Behavioral Health updated its TMS clinical policy to allow psychiatric mental health nurse practitioners to administer TMS therapy in states granting full practice authority, covering approximately 34.8 million lives and significantly broadening the pool of qualified clinicians.
- Market Demand: With the increasing shortage of psychiatrists in the U.S., BrainsWay believes that expanding the role of nurse practitioners in TMS therapy will improve patient access and reduce wait times, enabling more patients to benefit from clinically proven non-pharmacologic treatment options.
- Broad Support: In addition to Optum, multiple U.S. commercial payers and government payers, including the Department of Veterans Affairs and TRICARE West, have adopted similar coverage policies, further enhancing the role of nurse practitioners in TMS care while complying with applicable policy and regulatory frameworks.
- Technological Advantage: BrainsWay's Deep TMS™ platform technology has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials reinforcing its leadership position in the mental health sector.
See More
BrainsWay Enters Strategic Equity Financing Agreement with Hopemark
- Strategic Investment: BrainsWay has entered into a strategic equity financing agreement with Hopemark, initially investing $1.5 million with the potential for an additional $1.5 million based on milestones, aimed at enhancing access to and awareness of mental health treatments.
- Partnership Outlook: CEO Hadar Levy stated that this investment will allow BrainsWay to focus on advancing its business and technology while partnering with growth-oriented clinical platforms to enhance its market position.
- Hopemark's Strengths: Hopemark CEO Abid Nazeer emphasized that BrainsWay's investment not only provides growth capital but also brings a deep understanding of interventional psychiatry, aiding Hopemark in scaling efficiently and improving patient outcomes.
- Industry Impact: This collaboration signifies BrainsWay's further commitment to the mental health sector, expected to accelerate the application and market penetration of Deep TMS technology, driving overall business growth.
See More
BrainsWay Ltd Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BrainsWay Ltd reported a 35% increase in revenue to $15.5 million for Q1 2026, indicating strong demand and sustained growth potential in the deep TMS market.
- Continued Profitability Improvement: The company achieved its 11th consecutive quarter of profitability with net income exceeding $2.3 million, more than doubling year-over-year, reflecting the effectiveness of its business model and increased market acceptance.
- Accelerated Market Expansion: The company shipped 117 deep TMS systems in the quarter, a 44% increase year-over-year, expanding its total install base to approximately 1,820 systems, thereby solidifying its market position in mental health.
- Increased R&D and Marketing Investment: Despite rising sales and marketing expenses to $4.9 million and R&D expenses to $2.8 million, these investments are expected to drive future product innovation and market expansion, supporting the company's long-term growth strategy.
See More
BrainsWay Q1 Earnings Beat Expectations with Strong Guidance
- Strong Earnings Report: BrainsWay reported Q1 GAAP EPS of $0.06, beating expectations by $0.01, indicating sustained profitability and enhancing its competitive position in the market.
- Significant Revenue Growth: The company achieved Q1 revenue of $15.53 million, a 34.6% year-over-year increase, exceeding market expectations by $0.91 million, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a growth of 27% to 30% compared to 2025, showcasing confidence in future growth prospects.
- Profitability Outlook: The company anticipates operating income to be 13% to 14% of revenue, with adjusted EBITDA expected to range from $12 million to $14 million, indicating an anticipated growth of 86% to 100% over 2025, further solidifying its financial health.
See More
BrainsWay Reports Strong Q1 2026 Financial Results with 35% Revenue Growth
- Significant Revenue Growth: BrainsWay's Q1 2026 revenue surged 35% year-over-year to $15.5 million, indicating strong market demand for its non-invasive neurostimulation treatments and further solidifying its leadership position in the industry.
- Net Income Doubles: The company reported a net income of $2.3 million for Q1, more than doubling from $1.1 million in the prior year, reflecting significant improvements in cost control and operational efficiency, which enhances investor confidence.
- Guidance Reaffirmed: BrainsWay reiterated its full-year 2026 revenue guidance of $66 million to $68 million, representing a 27% to 30% increase year-over-year, while also projecting Adjusted EBITDA of $12 million to $14 million, showcasing confidence in future growth.
- Strong Market Demand: The shipment of 117 Deep TMS systems in Q1, a 44% increase from the previous year, indicates strengthened relationships with enterprise clients and sustained market demand for its products, suggesting ongoing growth potential ahead.
See More
BrainsWay Q1 Earnings Announcement Scheduled
- Earnings Release Date: BrainsWay is set to announce its Q1 earnings on May 13 before market open, with a consensus EPS estimate of $0.05, reflecting a substantial year-over-year increase of 150%, indicating a significant improvement in profitability.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $14.62 million, representing a 26.7% year-over-year growth, which underscores the company's ongoing expansion and increasing customer demand, further solidifying its market position.
- Outstanding Historical Performance: Over the past year, BrainsWay has exceeded EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating stability and reliability in its financial performance.
- Positive Revision Trends: In the last three months, both EPS and revenue estimates have seen three upward revisions with no downward adjustments, reflecting analysts' confidence in the company's future performance, which could positively impact its stock price.
See More
BrainsWay Advances TMS Treatment Coverage Policy Changes
- Policy Update: In late 2025, Optum/United Behavioral Health updated its TMS clinical policy to allow psychiatric mental health nurse practitioners to administer TMS therapy in states granting full practice authority, covering approximately 34.8 million lives and significantly broadening the pool of qualified clinicians.
- Market Demand: With the increasing shortage of psychiatrists in the U.S., BrainsWay believes that expanding the role of nurse practitioners in TMS therapy will improve patient access and reduce wait times, enabling more patients to benefit from clinically proven non-pharmacologic treatment options.
- Broad Support: In addition to Optum, multiple U.S. commercial payers and government payers, including the Department of Veterans Affairs and TRICARE West, have adopted similar coverage policies, further enhancing the role of nurse practitioners in TMS care while complying with applicable policy and regulatory frameworks.
- Technological Advantage: BrainsWay's Deep TMS™ platform technology has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials reinforcing its leadership position in the mental health sector.
See More
